Savara (SVRA) Long-Term Debt Repayments (2015 - 2025)

Savara (SVRA) reported Long-Term Debt Repayments of -$1000.0 for Q3 2025, down 100.0% quarter-over-quarter from $27.2 million in Q1 2025.

Savara (SVRA) Long-Term Debt Repayments (2015 - 2025) Analysis & Trends

Savara (SVRA) has 7 years of Long-Term Debt Repayments data on file, last reported at -$1000.0 in Q3 2025.

Long-Term Debt Repayments for Q3 2025 came in at -$1000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $27.2 million (changed N/A YoY), and the FY2025 annual result was $27.2 million, changed N/A from the prior year.
Long-Term Debt Repayments declined to -$1000.0 in Q3 2025 per SVRA's latest filing, from $27.2 million in the prior quarter.
Over five years, Long-Term Debt Repayments peaked at $27.2 million in Q1 2025 and troughed at -$1000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-21,671.00
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Savara	1.39 Bn	1.39 Bn	-	-

Download Data